BeOne Medicines, a bio/pharmaceutical company focused on oncology, has announced a $300-million expansion of its clinical and commercial-stage manufacturing and research and development center in Hopewell, New Jersey, bringing the company’s total US manufacturing investment to more than $1 billion. The company is globally headquartered in Basel, Switzerland, and has corporate and operational hubs in Cambridge, Massachusetts and Beijing, China and also operates manufacturing sites in Guangzhou and Suzhou, China. 

With this expansion, the campus will become a fully integrated, multi-platform manufacturing site, combining existing biologics production with new small-molecule drug-product capabilities. The expansion involves construction of a new three-story, 145,000-square-foot building adjacent to BeOne’s existing Hopewell facilities to bring the total campus footprint to approximately 545,000 square feet. The new building will house drug-product manufacturing and packaging operations alongside quality control laboratories, office space, and capacity reserved for future growth. Opened in July 2024 following an initial investment of $800 million, the latest $300-million expansion brings total investment at the Hopwell campus to more than $1 billion. As BeOne’s flagship US manufacturing and clinical R&D hub, the campus also supports clinical and commercial-stage biologics manufacturing for the company’s solid tumor portfolio. The 42-acre site features more than 1 million square feet of developable real estate for future growth. 

The expanded facility is anticipated to be fully operational in 2029.   

Source: BeOne Medicines